The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs. The agency published a draft guidance for industry Wednesday that would potentially make it faster and less costly for companies to develop biologics and bring them to market,